$58.34
Value $119B
BMY and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$58.34
Value $119B
$267.14
Value $644B
Bristol-Myers Squibb (BMY) has a market value of $119B and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, BMY moved +29.4% and JNJ +36.6%. The P/E is 12.9 for BMY and 40.0 for JNJ. Dividend yield: BMY 4.32%, JNJ 1.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
BMY$119B
JNJ$644B
JNJ is 5.4 times BMY
Revenue, 12 months
BMY$50.0B
JNJ$99.3B
JNJ is 2.0 times BMY
Net income, 12 months
BMY$9.2B
JNJ$16.1B
JNJ is 1.7 times BMY
Operating margin
BMY–
JNJ–
ROIC
BMY14.1%
JNJ12.4%
1.7 points apart
P/E
BMY12.9
JNJ40.0
JNJ is 3.1 times BMY
Dividend yield
BMY4.3%
JNJ2.0%
2.3 points apart
5-year return
BMY+21.5%
JNJ+89.1%
67.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
BMY+21.5%
JNJ+89.1%
| Period | BMYWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +29.4%Price +24.0% | +36.6%Price +33.6% |
| 3 years since November 17, 2023 | +32.1%+9.7% a yearPrice +14.8% | +94.2%+24.8% a yearPrice +78.3% |
| 5 years since November 18, 2021 | +21.5%+4.0% a yearPrice -1.2% | +89.1%+13.6% a yearPrice +64.5% |
| 10 years since November 21, 2016 | +46.9%+3.9% a yearPrice +2.8% | +202.7%+11.7% a yearPrice +132.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
BMYBristol-Myers SquibbJNJJohnson & Johnson
| Price | $58.34 | $267.14 |
|---|---|---|
| Market value | $119B | $644B |
| Enterprise value (EV) | $149B | $671B |
| P/E | 12.9 | 40.0 |
| P/E, 5-year median | 17.8 | 21.9 |
| P/B | 5.1 | 7.9 |
| EV/EBIT | 13.2 | 37.8 |
| Free cash flow yield | 7.8% | 3.2% |
| Revenue, 12 months | $50.0B | $99.3B |
|---|---|---|
| Net income, 12 months | $9.2B | $16.1B |
| Free cash flow, 12 months | $9.3B | $20.6B |
| Earnings per share, 12 months | $4.51 | $6.59 |
| Revenue growth, year on year | -0.2% | 6.1% |
| Revenue growth a year, past | +2.5%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | 69.2% | 67.6% |
|---|---|---|
| Operating margin | – | – |
| Net margin | 18.5% | 16.2% |
| ROIC | 14.1% | 12.4% |
| ROE | 45.0% | 19.7% |
| Cash | $12.6B | $17.2B |
|---|---|---|
| Total debt | $44.8B | $44.7B |
| Net debt / EBITDA | 2.0 | 1.1 |
| Interest cover | 6.9× | 18.0× |
| Dividend yield | 4.3% | 2.0% |
|---|---|---|
| Dividend per share, 12 months | $2.52 | $5.28 |
| Dividend growth a year, past | +6.2%over 5 years | +5.3%over 5 years |
| Buyback yield | – | 0.9% |
| Shareholder yield | 4.3% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($644B) is about 5.4 times Bristol-Myers Squibb ($119B), at today's prices.
Since November 21, 2016, BMY's price moved +2.8% and JNJ's +132.3%. With dividends: BMY +46.9% (+3.9% a year), JNJ +202.7% (+11.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is 4.32% for Bristol-Myers Squibb and 1.98% for Johnson & Johnson. Over the last twelve months they paid $2.52 and $5.28 per share.
At today's price, the P/E is 12.9 for BMY and 40.0 for JNJ. The median of the last five years was 17.8 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 18.5% for Bristol-Myers Squibb and 16.2% for Johnson & Johnson, and the operating margin – and –. Revenue was $50.0B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.